Schizophrenia can be a debilitating mental health disorder. Early diagnosis can help aid in its diagnosis and lead to a better outcome.
Schizophrenia can be a disabling mental health disorder. It’s characterized by symptoms such as hallucinations, delusions, disorganized communication and blunted effect. Although the incidence of the disorder is relatively low, this condition has a dramatic effect on the suffering individual, their families and their communities.
One way to lessen the hardships of this condition is an early diagnosis. To diagnose this disorder early, it is necessary to have the correct tools to perform schizophrenia screening.
Diagnostic Tools for Schizophrenia
The Diagnostic and Statistical Manual of Mental Disorders (DSM), published by the American Psychiatric Association, is the standard diagnostic tool used in mental health settings. However, there are a handful of other schizophrenia screening tools based on this book that psychologists also use to see if someone meets schizophrenia diagnostic criteria.
The Positive and Negative Syndrome Scale (PANSS) evaluates the positive and negative symptoms of schizophrenia. In this scale, positive symptoms refer to an excess or distortion of normal functions, such as hallucinations and delusions. Negative symptoms, on the other hand, represent a loss of normal functions such as effect and motivation.
The PANSS schizophrenia scale is a 30-item questionnaire. It was conceived as an operationalized, drug-sensitive instrument that provides a balanced representation of both positive and negative symptoms and determines their relationship to one another. In the 45-minute clinical interview, the patient is rated from 1–7 on 30 different symptoms based on the interview, as well as reports from family members or hospital workers. Studies have found this questionnaire to be both reliable and valid.
The Scale for the Assessment of Negative Symptoms (SANS), unlike the PANSS, is only used to measure the negative symptoms of schizophrenia. The SANS schizophrenia scale is a questionnaire comprised of 19 questions and is split into five domains of negative symptoms. Within each of these domains, these symptoms are rated from 0 (absent) to 5 (severe). Because it contains more questions than questionnaires that are typically used to screen for schizophrenia, it may yield more interpretable findings.
The Brief Psychiatric Rating Scale (BPRS) does not focus solely on schizophrenia symptoms. Instead, it is used to measure symptoms such as depression, anxiety, hallucinations and other similar behaviors. It is a 24-item questionnaire on which symptoms are rated on a 1–7 scale. The BPRS schizophrenia scale is slightly older than other questionnaires. However, the BPRS has been shown to be particularly good at capturing affective symptoms related to the manic dimension of schizophrenia.
The Clinical Global Impression-Schizophrenia (CGI-SCH) scale was designed to assess positive, negative, depressive and cognitive symptoms of schizophrenia. Research suggests that the CGI‐SCH scale is a valid and reliable questionnaire to evaluate severity and treatment response in schizophrenia. It has ten questions that are answered on a 1–7 scale. Simply put, it is simple, short, valid and has clinical value.
The Calgary Depression Scale for Schizophrenia (CDSS) is the only questionnaire designed for the assessment of depression in schizophrenia, and it differentiates between depression and the negative and positive symptoms of schizophrenia. It has nine questions that are answered on a 0–3 scale. One study suggests that the CDSS may provide the best assessment for depression in patients with schizophrenia.
The Importance of Early Diagnosis
Early diagnosis of schizophrenia is important. If diagnosed early, it will be easier to manage the symptoms later. Psychiatrists believe that early diagnosis and treatment may prevent social disability later. Because it is a disease that places such a heavy burden on individuals, their families and society, early diagnosis is essential.
Another thing that makes schizophrenia so deleterious of a condition is that it is often associated with substance abuse, as people with schizophrenia try to self medicate. This propensity for people with schizophrenia to abuse drugs actually has a biological basis within the brain.
Saha, Sukanta; et al. “A systematic review of the prevalence of schizophrenia.” PLoS medicine, 2005. Accessed September 27, 2019.
American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of men[…]s: DSM-5™ (5th ed.). 2013. Accessed September 27, 2019.
Kay, Stanley R.; Fiszbein, Abraham; Opler, Lewis A. “The positive and negative syndrome scale[…]S) for schizophrenia.” Schizophrenia bulletin, 1987. Accessed September 27, 2019.
Blanchard, Jack J.; Cohen, Alex S. “The structure of negative symptoms withi[…]tions for assessment.” Schizophrenia bulletin, 2005. Accessed September 27, 2019.
Kumari, Suneeta, et al. “An assessment of five (PANSS, SAPS, SANS[…]scales (CAINS, BNSS).” Journal of addiction research & therapy, 2017. Accessed September 27, 2019.
Ventura, Joseph, et al. “Symptom dimensions in recent-onset schiz[…]hiatric Rating Scale.” Psychiatry research, 2000. Accessed October 15, 2019.
Frangou, Sophia; Byrne, Patrick. “How to manage the first episode of schiz[…]ial disability later.” BMJ, 2000. Accessed September 27, 2019.
Chambers, R; Krystal, Andrew, John H.; and Self, David W. “A neurobiological basis for substance ab[…]ity in schizophrenia.” Biological psychiatry, 2001. Accessed September 27, 2019.
The Recovery Village aims to improve the quality of life for people struggling with substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare providers.